Healthcare companies play a primary role in conducting and funding health research and development (R&D), investing more than USD 50 billion each year. During 2010, Novartis invested USD 8.1 billion in core R&D – one of the highest figures in the industry relative to sales (16%).
Targeting rare and neglected diseases
Our research strategy targets rare diseases where there is real unmet medical need and good scientific understanding of how the disease works. We also research treatments and vaccines for diseases of the developing world through two specialized institutes:
- The Novartis Institute for Tropical Diseases (NITD) in Singapore
- The Novartis Vaccines Institute for Global Health (NVGH) in Siena, Italy
- Learn more about our research
Our efforts to push the boundaries of knowledge in the field of human health may give rise to ethical issues, such as those involved in animal welfare or stem cell research. We recognize the importance of informed stakeholder debate on such issues and welcome the opportunity to engage in constructive dialogue.
Novartis’ positions on:
- Animal research
- Clinical trials in the developing world
- Disclosure of clinical research information